Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT

The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.
Medscape Medical News

source https://www.medscape.com/viewarticle/998373?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost